Potential novel uses of thalidomide: Focus on palliative care

Drugs

Volumn 60, Issue 2, 2000, Pages 273-292

  Peuckmann, V ^a   Fisch, M ^b   Bruera, E ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; APHTHOUS ULCER; BEHCET DISEASE; CACHEXIA; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ERYTHEMA NODOSUM LEPROSUM; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPATHY; PALLIATIVE THERAPY; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SARCOIDOSIS; TERATOGENICITY; TREATMENT INDICATION; TUBERCULOSIS;

EID: 0033857366     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060020-00003     Document Type: Review

References (120)

1. Thalidomide and congenital abnormalities
2. Thalidomide and congenital abnormalities
3. Thalidomide: A revival story
4. Thalidomide in rabbit semen
5. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species
6. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha
7. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
8. Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations
9. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
10. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
11. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
12. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
13. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis
14. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
15. Inhibition of IL-12 production by thalidomide
16. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
17. Thalidomide prolongs experimental autoimmune neuritis in Lewis rats
18. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells
19. Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer
20. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus
21. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group
22. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL)
23. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial
24. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide
25. Corticosteroid therapy of preterminal gastrointestinal cancer
26. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative
27. Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro
28. Does thalidomide affect IL-2 response and production?
29. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures
30. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha
31. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin
32. Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium
33. Thalidomide is an inhibitor of angiogenesis
34. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor
35. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo
36. A comparative clinical trial in the elderly of Distaval, Doriden, and Welldorm, three non-barbiturate hypnotics
37. Genital malformations in thalidomide-damaged girls
38. Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief
39. Detection of contergan and doriden, especially in cadavers
40. Reference to central nervous system damage within the context of thalidomide embryopathy: Pathologic-anatomic, electroencephalographic and neurologic findings
41. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients
42. Thalidomide in the treatment of lepra reactions
43. Nature of the retrograde signal from injured nerves that induces interleukin-6 mRNA in neurons
44. A phase I/II trial of thalidomide as an anti-angiogenic agent in the treatment of advanced cancer
45. Continous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
46. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer
47. Antitumor activity of thalidomide in refractory multiple myeloma
48. Thalidomide (N-phthaloyl-glutamimide) in the treatment of advanced cancer
49. The effect of thalidomide on experimental tumors and metastases
50. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid
51. Effect of thalidomide on a variety of transplantable tumors
52. Clinical experiences with thalidomide in patients with cancer
53. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report
54. Thalidomide. A promising new treatment for rheumatoid arthritis
55. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum
56. Thalidomide in acute symptoms in leprosy (erythema nodosum or multiforme)
57. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation
58. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy
59. Mouth and pharyngeal hyperalgesic syndromes in AIDS
60. Thalidomide in the treatment of aphthosis and Behcet's disease. 4 years' experience
61. Treatment of aphthosis with thalidomide and with colchicine
62. The effect of thalidomide on the pathogenesis of human immuno-deficiency virus type I and M. tuberculosis infection
63. Effect of thalidomide on the graft versus host reaction
64. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children
65. Thalidomide for the treatment of chronic graft-versus-host disease
66. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease
67. Treatment of refractory rheumatoid arthritis: The thalidomide experience
68. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
69. Sleep
70. Rapid discontinuation of hypnotics in terminal cancer patients: A prospective study
71. Phase I trial of thalidomide in AIDS-related kaposi sarcoma (ks)
72. Asthenia-cachexia
73. The pathophysiology of cachexia in advanced cancer and AIDS
74. Areview of the drug treatment of cachexia associated with cancer
75. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins
76. Interleukin-8 modulates feeding by direct action in the central nervous system
77. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice
78. Involvement of human interleukin 6 in experimental cachexia induced by human uterine cervical carcinoma xenograft
79. Chronic nausea
80. Use of imide of N-phthalyl-glutamic acid (thalidomide) in the symptomatic therapy of vomiting of many patients with malignant neoplasms or caused by administration of mechlorethamine HCl
81. Effectiveness of megestrol acetate in patients with advanced cancer: A randomized, double-blind, crossover study
82. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia
83. Clenbuterol, a beta-adrenoreceptor agonist, increases muscle strength in orthopaedic patients
84. The assessment of nutritional status, caloric intake, and appetite in patients with advanced cancer
85. Molecular basis of fever in humans
86. Demonstration of circulating leukocytic pyrogen/interleukin I during fever
87. Unmyelinated nerve fibers in senile nerves and in late thalidomide neuropathy: A quantitative electron microscopic study
88. Thalidomide for distressing night sweats in advanced malignant disease
89. Thalidomide for night sweats in patients with advanced cancer
90. The treatment of cancer pain
91. The Edmonton staging system for cancer pain: Preliminary report
92. Neurotrophins and their receptors in nerve injury and repair
93. Interleukin-6 mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model
94. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve
95. Interleukin-6 mRNA expression by cortical neurons in culture: Evidence for neuronal sources of interleukin-6 production in the brain
96. Quantification of interleukin-6 mRNA in wallerian degeneration by competitive reverse transcription polymerase chain reaction
97. Differential modulation of short and long latency sensory responses in the Si cortex by IL-6
98. Are thalidomide and its biological metabolites vitamin antagonists
99. Teratogenic action of thalidomide
100. Thalidomide and the B vitamins
101. Are thalidomide and its biological metabolites antagonists of glutamic acid
102. An attempted reversal of thalidomide embryopathy in the rat by glutamine
103. Structural relationship between thalidomide and nucleosides
104. Thalidomide and congenital abnormalities of the eye
105. Minor ocular abnormalities associated with thalidomide
106. Chromosomal studies on so-called thalidomide embryopathy
107. Another chance for thalidomide?
108. Chromosome aberrations in human cells induced by thalidomide in vitro: Preliminary report
109. Thalidomide is not a mutagen
110. Does thalidomide cause second generation birth defects?